ArticleMolecular therapy. Nucleic acids2026
Therapeutic potential of ISG20 in attenuating podocyte injury via inhibition of ferroptosis.
Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- mRNA vaccine development for tuberculosis: antigen design, immune mechanisms, and translational challenges.Archives of microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis, an iron-dependent form of cell death characterized by lipid peroxidation, has been recognized as a critical mechanism contributing to podocyte injury in diabetic kidney disease (DKD). Although interferon-stimulated gene 20 (ISG20) has been identified as a novel regulator of RNA oxidation stress in acute kidney disease, its specific role and mechanism in DKD remain to be elucidated. In this study, we investigated the role of ISG20 in ferroptosis and its potential as a therapeutic target in DKD. We found that ISG20-deficient mice exhibited excessive iron accumulation, increased lipid peroxidation, and markedly higher proteinuria compared to wild-type mice. Nevertheless, the administration of a ferroptosis inhibitor, ferrostatin-1(Fer-1), mitigated kidney injury. Consistent results were observed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.